MATN3 and cancer: The expression of MATN3 was negatively correlated with Dasatinib32, Elesclomol33, Erlotinib34, and Lapatinib35, suggesting that MATN3 may promote the sensitivity of this part of drugs and play a positive role in cancer treatment.